Pam2CSK4 |
Catalog No.GC10058
One-Click Copy Product Info
|
Pam2CSK4 is a potent agonist of TLR2/TLR6, with an EC50 value of 0.015ng/ml.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 868247-72-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Pam2CSK4 is a potent agonist of TLR2/TLR6, with an EC50 value of 0.015ng/ml[1]. Pam2CSK4 can activate the platelet nuclear factor-κB and Bruton's tyrosine kinase signaling pathway to promote platelet-endothelial cell interaction[2]. Pam2CSK4 has been widely used as an adjuvant for the development of novel vaccines that can significantly improve the titer of antigen-specific neutralizing antibodies and the persistence of humoral immunity[3].
In vitro, Pam2CSK4 treatment (100ng/ml) of nucleus pulposus (NP) cells isolated from nondegenerative intervertebral discs for 48 hours significantly increased the secretion of several proinflammatory cytokines and chemokines such as IL-6, IL-8, CXCL1, GRO, and CCL2[4]. Treatment of RAW264.7 cells with 100ng/ml Pam2CSK4 for 6 hours significantly promoted the expression of iNOS and stimulated the production of NO[5]. Treatment of peripheral blood mononuclear cells (PBM) with 100ng/ml Pam2CSK4 for 24 hours synergistically enhanced IgG-mediated TNFα production and significantly upregulated Fcγ receptor (FcγR) expression[6].
In vivo, Pam2CSK4 administration via intraperitoneal injection at a dose of 250μg/kg/day for 8 days significantly promoted weight gain and colon length increase during colitis onset and alleviated colitis damage in mice[7].
References:
[1] Irvine K L, Hopkins L J, Gangloff M, et al. The molecular basis for recognition of bacterial ligands at equine TLR2, TLR1 and TLR6[J]. Veterinary research, 2013, 44(1): 50.
[2] Parra-Izquierdo I, Lakshmanan H H S, Melrose A R, et al. The toll-like receptor 2 ligand Pam2CSK4 activates platelet nuclear factor-κB and Bruton’s tyrosine kinase signaling to promote platelet-endothelial cell interactions[J]. Frontiers in Immunology, 2021, 12: 729951.
[3] Qiao Y, Zhan Y, Zhang Y, et al. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses[J]. Frontiers in immunology, 2022, 13: 992062.
[4] Krock E, Rosenzweig D H, Currie J B, et al. Toll-like receptor activation induces degeneration of human intervertebral discs[J]. Scientific reports, 2017, 7(1): 17184.
[5] Kulsantiwong P, Pudla M, Srisaowakarn C, et al. Pam2CSK4 and Pam3CSK4 induce iNOS expression via TBK1 and MyD88 molecules in mouse macrophage cell line RAW264. 7[J]. Inflammation Research, 2017, 66(10): 843-853.
[6] Shah P, Fatehchand K, Patel H, et al. Toll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function[J]. Journal of Biological Chemistry, 2013, 288(17): 12345-12352.
[7] Wang Y, Han J, Yang G, et al. Therapeutic potential of the secreted Kazal-type serine protease inhibitor SPINK4 in colitis[J]. Nature Communications, 2024, 15(1): 5874.
| Cell experiment [1]: | |
Cell lines | Caco-2 cells |
Preparation Method | Caco-2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin in a humidified incubator at 37℃ with 5% CO2. Caco-2 cells (4×105cells/ml) were seeded in 96-well culture plates and cultured until complete confluence. Cells were cultured in serum-free DMEM medium for 18h and then treated with 0.1µg/ml Pam2CSK4 for 24h. Cell culture supernatants were collected and IL-8 production was measured. |
Reaction Conditions | 0.1µg/ml; 24h |
Applications | Pam2CSK4 treatment significantly enhanced IL-8 levels in Caco-2 cells. |
| Animal experiment [2]: | |
Animal models | BALB/c mice |
Preparation Method | BALB/c mice were raised in a standard environment and had free access to food and water. 3% dextran sulfate sodium (DSS), with a molecular weight of 36,000-50,000Da, was added to the drinking water of the mice for 7 days. At the same time, from the first day of DSS administration, Pam2CSK4 was intraperitoneally injected for 8 consecutive days at a dose of 250μg/kg/day. The mouse samples were collected for analysis. |
Dosage form | 250μg/kg/day for 8 days; i.p. |
Applications | Pam2CSK4 treatment promoted weight gain and colon length increase during colitis onset and alleviated colitis damage in mice. |
References: | |
| Cas No. | 868247-72-7 | SDF | |
| Chemical Name | (2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17R,21R)-17-amino-2,5,8,11-tetrakis(4-aminobutyl)-4,7,10,13,16-pentahydroxy-14-(hydroxymethyl)-24-oxo-21-(palmitoyloxy)-23-oxa-19-thia-3,6,9,12,15-pentaazanonatriaconta-3,6,9,12,15-pentaen-1-oic acid | ||
| Canonical SMILES | CCCCCCCCCCCCCCCC(OC[C@](OC(CCCCCCCCCCCCCCC)=O)([H])CSC[C@@](N)([H])/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](C(O)=O)([H])CCCCN)([H])CCCCN)([H])CCCCN)([H])CCCCN)([H])CO)=O | ||
| Formula | C65H126N10O12S | M.Wt | 1271.83 |
| Solubility | Soluble to 1 mg/ml in 0.25% acetic acid | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 786.3 μL | 3.9313 mL | 7.8627 mL |
| 5 mM | 157.3 μL | 786.3 μL | 1.5725 mL |
| 10 mM | 78.6 μL | 393.1 μL | 786.3 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)